<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>medsurfnews.com</title><link>http://www.medsurfnews.com</link><description>Le ultime risorse da Medsurfnews.com</description><language>it</language><pubDate></pubDate><copyright>Healthware.it</copyright><webmaster>francesco.raimondo@healthware.it</webmaster><image><title>Medsurfnews Rss</title><url>http://www.medsurfnews.com/images/logo.jpg</url><link>http://www.medsurfnews.com</link></image>
	
	
	
<item>
<category>Reumatologia</category>
<title>Monoarticular Arthritis</title>
<link>http://www.medsurfnews.com/contents/it/7017/display/monoarticular-arthritis.aspx</link>
<description><![CDATA[In Holland, a diagnostic rule has been developed for gout, using the data of 381 consecutive patients arrived at the general practitioner because affected by monoarthritis. Within 24 hours from examination, they underwent arthrocentesis, an examination on synovial fluid to search monosodium urate (MSU) crystals, medical examination and laboratory examinations.]]></description>
<pubDate>Mon, 30 Jan 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>New Classification Criteria for Rheumatoid Arthritis</title>
<link>http://www.medsurfnews.com/contents/it/6996/display/new-classification-criteria-for-rheumatoid-arthritis.aspx</link>
<description><![CDATA[The American College of Rheumatology and the European League Against Rheumatism have developed together some new criteria for the classification of rheumatoid arthritis, changing the ones previously published (in 1987). First of all, a working group has examined the data from wide cohort trials on patients affected by early synovitis, to identify possible predictive factors and possible prognostic modifications to be obtained with therapy. Secondly, a group of experts of this disease has established the fundamental predictive factors.]]></description>
<pubDate>Mon, 23 Jan 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Pregnancy Safe for Most Women With Lupus: Study</title>
<link>http://www.medsurfnews.com/contents/it/6842/display/pregnancy-safe-for-most-women-with-lupus-study.aspx</link>
<description><![CDATA[In this study, researchers identified a few predictors of lupus-related pregnancy complications, but also found that most women with stable lupus had successful pregnancies. The findings were to be presented Nov. 7 at the American College of Rheumatology annual meeting in Chicago.



]]></description>
<pubDate>Mon, 7 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Incidence and Prevalence of Rheumatoid Arthritis in Women</title>
<link>http://www.medsurfnews.com/contents/it/6847/display/incidence-and-prevalence-of-rheumatoid-arthritis-in-women.aspx</link>
<description><![CDATA[Even if genetic factors certainly have an important role, at the basis of the incidence and prevalence of rheumatoid arthritis, no doubt, there are other factors. In order to verify the extent of this disease, some researchers at Mayo Clinic have examined the data relative to cases of rheumatoid arthritis diagnosed in Olmsted, Minnesota, between 1995 and 2007.]]></description>
<pubDate>Mon, 7 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Final guidance on abatacept for rheumatoid arthritis</title>
<link>http://www.medsurfnews.com/contents/it/6663/display/final-guidance-on-abatacept-for-rheumatoid-arthritis.aspx</link>
<description><![CDATA[The guidance does not recommend abatacept in combination with methotrexate, for treating rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying anti-rheumatic drugs (DMARDs) including methotrexate. ]]></description>
<pubDate>Mon, 29 Aug 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>NICE recommends new drug for rheumatoid arthritis</title>
<link>http://www.medsurfnews.com/contents/it/6561/display/nice-recommends-new-drug-for-rheumatoid-arthritis.aspx</link>
<description><![CDATA[In final guidance, the National Institute for Health and Clinical Excellence (NICE) recommends golimumab (Simponi) as an option for treating rheumatoid arthritis in specific circumstances where previous treatments haven?t worked. Golimumab joins a list of treatment options already recommended by NICE for this condition.
]]></description>
<pubDate>Mon, 27 Jun 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm</title>
<link>http://www.medsurfnews.com/contents/it/6433/display/rheumatoid-arthritis-may-raise-risk-of-abnormal-heart-rhythm.aspx</link>
<description><![CDATA[People with two common inflammatory diseases stand a higher chance of developing a heart condition that is strongly associated with stroke, a new study suggests. The study, done at the University of Arkansas for Medical Sciences, found that patients with lupus and rheumatoid arthritis have a 60 percent increased risk for atrial fibrillation, an abnormal heart rhythm (arrhythmia) linked to stroke.

]]></description>
<pubDate>Tue, 10 May 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Golimumab for the treatment of psoriatic arthritis</title>
<link>http://www.medsurfnews.com/contents/it/6421/display/golimumab-for-the-treatment-of-psoriatic-arthritis.aspx</link>
<description><![CDATA[The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending golimumab (Simponi) for the treatment of psoriatic arthritis. Golimumab joins a list of treatment options already recommended by NICE for this condition. The guidance recommends golimumab as an option for treating active and progressive psoriatic arthritis in adults if it is used as described for the other tumour necrosis factor (TNF) inhibitor treatments - etanercept, infliximab and adalimumab - covered by NICE technology appraisal.  The recommendation of golimumab is also on the condition that the manufacturer provides the 100 mg dose of golimumab to the NHS at the cost of the 50 mg dose, as agreed by the manufacturer and the Department of Health as part of a patient access scheme.
]]></description>
<pubDate>Tue, 3 May 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay</title>
<link>http://www.medsurfnews.com/contents/it/6005/display/diagnostic-performance-and-validation-of-autoantibody-testing-in-myositis-by-a-commercial-line-blot-assay.aspx</link>
<description><![CDATA[Serological testing for myositis-specific or associated autoantibodies [myositis-specific antibody (MSA) and myositis-associated antibody (MAA)] is useful for the diagnosis of idiopathic inflammatory myopathies (IIMs). Line blot could be a suitable serological test in the diagnostic workup for myositis, and it represents a reliable alternative to more time-consuming procedures. Continuous effort is recommended in order to improve its accuracy.
]]></description>
<pubDate>Mon, 15 Nov 2010 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Reumatologia</category>
<title>Rheumatoid Arthritis May Raise Risk of Blood Vessel Plaque</title>
<link>http://www.medsurfnews.com/contents/it/5970/display/rheumatoid-arthritis-may-raise-risk-of-blood-vessel-plaque.aspx</link>
<description><![CDATA[Certain medications seem to lessen or increase buildup, suggests study.]]></description>
<pubDate>Tue, 9 Nov 2010 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	</channel></rss>
	



